ZIOPHARM Oncology to Host Conference Call on November 20, 2017 at 10:15 a.m. ET to Discuss Updated Clinical Data Presented at...
November 17 2017 - 7:00AM
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company
developing new gene and cell-based immunotherapies for cancer,
today announced that it will host a conference call and webcast
slide presentation on Monday, November 20, 2017 at 10:15 a.m. ET to
discuss updated clinical data from the Company's controlled human
interleukin-12 (hIL-12) gene therapy candidate for brain cancer to
be presented at the 22nd Annual Meeting and Education Day of the
Society for Neuro-Oncology (SNO), held Nov. 16 - 19 in San
Francisco.
In addition to members of the ZIOPHARM
management team, joining the conference call will be key thought
leaders and study investigators Antonio Chiocca, M.D., Ph.D.,
Professor of Neurosurgery at Harvard Medical School, Surgical
Director, Center for Neuro-oncology at Dana-Farber Cancer
Institute, and Chairman of Neurosurgery and Co-Director of the
Institute for the Neurosciences at Brigham and Women's Hospital,
and Stewart Goldman, M.D., Division Head Hematology-Oncology,
Neuro-Oncology & Stem Cell Transplantation at Ann & Robert
H. Lurie Children's Hospital in Chicago.
The call can be accessed by dialing
1-844-309-0618 (U.S. and Canada) or 1-661-378-9465 (international).
The conference ID number is 8089664. To access the accompanying
slides and live webcast, or the subsequent archived recording,
visit the "Investors & Media" section of the ZIOPHARM website
at www.ziopharm.com. The webcast will be recorded and available for
replay on the Company's website for two weeks.
About ZIOPHARM Oncology,
Inc.:
ZIOPHARM Oncology is a Boston,
Massachusetts-based biotechnology company employing innovative gene
expression, control and cell technologies to deliver safe,
effective and scalable cell- and viral-based therapies for the
treatment of cancer and graft-versus-host-disease. The Company's
immuno-oncology programs, in collaboration with Intrexon
Corporation (NYSE:XON) and the MD Anderson Cancer Center, include
chimeric antigen receptor T cell (CAR-T) and other adoptive
cell-based approaches that use non-viral gene transfer methods for
broad scalability. The Company is advancing programs in multiple
stages of development together with Intrexon Corporation's
RheoSwitch Therapeutic System® (RTS®) technology, a switch to turn
on and off, and precisely modulate, gene expression in order to
improve therapeutic index. The Company's pipeline includes a number
of cell-based therapeutics in both clinical and preclinical testing
which are focused on hematologic and solid tumor malignancies.
Trademarks
RheoSwitch Therapeutic System® and RTS® are
registered trademarks of Intrexon Corporation.
Contact:
David ConnollyZIOPHARM
Oncology617-502-1881dconnolly@ziopharm.com
David PittsArgot
Partners212-600-1902david@argotpartners.com
ZIOPHARM Oncology (NASDAQ:ZIOP)
Historical Stock Chart
From Aug 2024 to Sep 2024
ZIOPHARM Oncology (NASDAQ:ZIOP)
Historical Stock Chart
From Sep 2023 to Sep 2024